ReviewTrends in cardiovascular medicine2016
Regression of coronary atherosclerosis: Current evidence and future perspectives.
Review in Trends in cardiovascular medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 30 citations in OpenAlex.
- Pharmacokinetic interaction between atorvastatin and fixed-dose combination of sofosbuvir/ledipasvir in healthy male Egyptian volunteers.European journal of clinical pharmacology · 2021Trial
- Effects of Green Tea Extract on Atorvastatin Pharmacokinetics in Healthy Volunteers.European journal of drug metabolism and pharmacokinetics · 2020Trial
- Identification of diagnostic biomarkers and immune cell infiltration in coronary artery disease by machine learning, nomogram, and molecular docking.Frontiers in immunology · 2024Article
- Statins in High Cardiovascular Risk Patients: Do Comorbidities and Characteristics Matter?International journal of molecular sciences · 2022Review
- Silencing Myeloid Netrin-1 Induces Inflammation Resolution and Plaque Regression.Circulation research · 2021Article
- Effects of different statins application methods on plaques in patients with coronary atherosclerosis.World journal of clinical cases · 2021Article
- Correlation between angiopoietin-like proteins in inflammatory mediators in peripheral blood and severity of coronary arterial lesion in patients with acute myocardial infarction.Experimental and therapeutic medicine · 2019Article
- The Effects of Pitavastatin on Nuclear Factor-Kappa B and ICAM-1 in Human Saphenous Vein Graft Endothelial Culture.Cardiovascular therapeutics · 2019Article
- Statins and Inflammation: New Therapeutic Opportunities in Psychiatry.Frontiers in psychiatry · 2019Review
- The multifaceted link between inflammation and human diseases.Journal of cellular physiology · 2018Review
- The Role ofNutrients · 2018Review
- The Anti-Inflammatory Effects of Statins on Coronary Artery Disease: An Updated Review of the Literature.Current cardiology reviews · 2017Review
- Biodegradable Metals for Cardiovascular Stents: from Clinical Concerns to Recent Zn-Alloys.Advanced healthcare materials · 2016Review
- Coronary plaque burden regression and high-risk plaque reversal: Potential biomarkers for secondary prevention?Trends in cardiovascular medicine · 2016Article
Corrections and comments
- Commented on by
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronary atherosclerosis has been considered a chronic disease characterized by ongoing progression in response to systemic risk factors and local pro-atherogenic stimuli. As our understanding of the pathobiological mechanisms implicated in atherogenesis and plaque progression is evolving, effective treatment strategies have been developed that led to substantial reduction of the clinical manifestations and acute complications of coronary atherosclerotic disease. More recently, intracoronary imaging modalities have enabled detailed in vivo quantification and characterization of coronary atherosclerotic plaque, serial evaluation of atherosclerotic changes over time, and assessment of vascular responses to effective anti-atherosclerotic medications. The use of intracoronary imaging modalities has demonstrated that intensive lipid lowering can halt plaque progression and may even result in regression of coronary atheroma when the highest doses of the most potent statins are used. While current evidence indicates the feasibility of atheroma regression and of reversal of presumed high-risk plaque characteristics in response to intensive anti-atherosclerotic therapies, these changes of plaque size and composition are modest and their clinical implications remain largely elusive. Growing interest has focused on achieving more pronounced regression of coronary plaque using novel anti-atherosclerotic medications, and more importantly on elucidating ways toward clinical translation of favorable changes of plaque anatomy into more favorable clinical outcomes for our patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.